Anhui Anke Biotechnology (300009.SZ) appoints Dou Changlin as the company's Chief Executive Officer and Chief Scientist.

Anhui Anke Biotechnology (300009.SZ) released an announcement stating that the company's ninth board of directors' third meeting approved the "Proposal on the Appointment of Senior Management Personnel," agreeing to appoint Dr. Dou Changlin as the company's Chief Executive Officer and Chief Scientist. Dr. Dou will be primarily responsible for the construction of the company's innovative drug research and development system, establishment of cutting-edge technology platforms, global layout, advancement of key pipelines, and management of research and development teams. His term will be from the date of approval of this board of directors' meeting until the expiration of this board's term. It is reported that Dr. Dou Changlin is a leading expert and senior manager in the global biopharmaceutical field, with over twenty-six years of top-notch research and development and management experience in biopharmaceutical companies at home and abroad. He has made remarkable achievements in the full-cycle research and development of innovative drugs, establishment of key technology platforms, clinical development, and industrialization. Dr. Dou has held senior research and development management positions in several well-known biotech companies, leading teams to commercialize multiple blockbuster biopharmaceuticals. He possesses a profound scientific perspective, mature management experience, and rich industrialization and practical capabilities.